Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CD371 CAR IL18 T cell therapy - Memorial Sloan Kettering Cancer Center/Takeda

Next Previous
Search
Drug Profile

CD371 CAR IL18 T cell therapy - Memorial Sloan Kettering Cancer Center/Takeda

Alternative Names: CD371-SAVVYz-IL18 Car T cell therapy - Takeda; CD371-YSNVZIL-18 CAR T Cells - Takeda

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda Development Center Americas
  • Developer Memorial Sloan-Kettering Cancer Center; Takeda Development Center Americas
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Interleukin 18 stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 07 Dec 2024 Pharmacodynamics and efficacy data from a phase-I trial in Acute myeloid leukemia presented at the 66th American Society of Hematology Annual Meeting and Exposition
  • 22 Aug 2023 Phase-I clinical trials in Acute myeloid leukaemia (In adolescents, In adults, In children, In the elderly, In infants) in USA (IV) (NCT06017258),

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top